Sengenics

LifeCodexx's PrenaTest will be available to women in Malaysia, Singapore, Thailand, Brunei, Vietnam, the United Arab Emirates, and elsewhere in the Middle East.

The companies are launching new clinical exome sequencing services called Exomax.

Sengenics has been employing the technology, which uses arrays of full-length, folded proteins, with a number of pharma clients for the last several years.

Sengenics is rebranding the technology Immunome and expects it to expand the company's footprint in the proteomics space.

NEW YORK (GenomeWeb) – Sengenics said this week that it has exclusively partnered with Sequenom to launch that company's VisibiliT non-invasive prenatal test in Thailand, Indonesia, and Brunei.

Kuwaiti molecular diagnostics firm Genatak has begun offering a targeted hereditary breast cancer panel and exome sequencing services for patients with cancer, undiagnosed genetic disorders, and individuals looking to understand disease risk.

NEW YORK (GenomeWeb News) – The Genome Institute of Singapore and Sengenics said today that they have formed a partnership to identify and validate auto-antibody signatures for the early detection of cancers.

NEW YORK (GenomeWeb News) – Sengenics and Parkway Laboratory Services have entered into a partnership to offer genetics tests in Singapore, Sengenics said on Thursday.

NEW YORK (GenomeWeb News) – CollabRx today announced a deal with Sengenics to incorporate each other's products into molecular diagnostics tests and reports aimed at cancer.

Oxford Gene Technology, a UK firm perhaps better known for its menu of chromosomal microarrays and foundational array IP, has seen its protein array platform emerge from the shadows in recent weeks after signing an agreement that gives its main partner in Asia the ability to offe

Pages

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.